Other tumour-derived biomarkers have been reported recently, including high tumour mutational load [57], presence of TILs in the tumour microenvironment [58, 59], increased PD-L1 expression on immune cells, high ratio of CD8+/CD4+ lymphocytes [53] and chromosomal aneuploidy [60]. This evidence concerns the gene CD4 and neoplasm.